Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease on July 09, 2026 Allogeneic Allogeneic Anti-CD19 1XX-CAR T-cells FT819 Autoimmune Diseases Automobiles B-Lymphocytes Depletion Encephalitis, St. Louis FT839 Identifier Lupus Erythematosus, Systemic Lupus Nephritis Phase 1/II RMAT +
In another reversal, FDA gives uniQure accelerated approval path for Huntington's gene therapy on June 18, 2026 Accelerated AMT-130 Approved Biologics License Application Breakthrough Therapy cUHDRS gene therapy Huntington 's disease NEFL gene Phase I/II study RMAT uniQure United States Food and Drug Administration +
FDA Policy on RMAT Designations for Therapies on Clinical Hold Remains Unchanged on March 19, 2026 gene therapy Identifier Regenerative Medicine regulatory policy RMAT Study on Hold United States Food and Drug Administration +
Forging the Future of Cell Therapy: Bayer and BlueRock's Unique Journey on June 06, 2025 Bayer bemdaneprocel biotech partnerships BlueRock Therapeutics Cell Therapy Identifier Parkinson 's disease Phase 3 trials Regenerative Medicine RMAT +
Forging the Future of Cell Therapy: Bayer and BlueRock's Unique Journey on June 05, 2025 Bayer bemdaneprocel biotech partnerships BlueRock Therapeutics Cell Therapy Identifier Parkinson 's disease Phase 3 trials Regenerative Medicine RMAT +
Neurona nabs $102M to launch pivotal trial of epilepsy cell therapy on April 04, 2025 Cell Therapy drug-resistant Epilepsy Identifier MTLE RMAT +